Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Apr 2017: Trial registered, NCT03128359
  2. 30 May 2017: Trial started, NCT03128359

The trials

NCT03128359: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

State
Completed
Phase
Phase 2
People
38 taking part
Started
30 May 2017
Primary completion
1 Aug 2020
Arms
Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)
Results
Posted on the registry
  1. 25 Apr 2017: Trial registered
  2. 30 May 2017: Trial started
  3. 15 Sep 2021: Trial completed
  4. 9 Jun 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.